ReviewBasic & clinical pharmacology & toxicology2025
Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review.
Review in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review.Basic & clinical pharmacology & toxicology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRaltegravir, an HIV integrase inhibitor, although generally well tolerated, may cause severe reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS). This syndrome has been associated with impaired drug metabolism, viral reactivation and genetic factors including HLA-B*53:01. We describe two cases of DRESS in a raltegravir-treated cohort and review the relevant literature. METHODOLOGY: Medical records from Hospital Universitario de La Princesa (2008-2020) were retrospectively reviewed to identify patients genotyped for HLA-B*53 who received raltegravir. Suspected DRESS cases were assessed using the RegiSCAR scoring system and Naranjo algorithm. A structured literature search was conducted to identify additional published cases.
resultsAmong 109 patients treated with raltegravir, three (2.8%) were HLA-B*53 carriers. Two developed DRESS, while no events occurred in non-carriers. One presented with fever, rash, lymphadenopathy, hepatitis and HHV-6 reactivation (RegiSCAR 6). The second developed eosinophilia, rash and pulmonary symptoms (RegiSCAR 4). The third carrier remained asymptomatic. A continuity correction yielded a RR of 133.9. Nine additional cases were identified in the literature and summarized according to clinical features and HLA-B*53 status.
conclusionFindings support a potential genetic predisposition involving HLA-B*53:01 in raltegravir-induced DRESS. Screening in high-prevalence populations may help prevent severe reactions. Further research should refine diagnostic and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.